Senda Biosciences
Senda: Innovatively harnessing molecular interactions for advanced medicine development.
Senda: Innovatively harnessing molecular interactions for advanced medicine development.
Senda Biosciences, a Flagship Pioneering company, was founded with the mission to harness the powerful molecular interactions between humans, plants, and bacteria to develop innovative medicines. The company focuses on creating programmable medicines using advanced bioplatforms powered by evolution and artificial intelligence. Senda’s offerings include first-in-category translatable circular RNA technology (Endless RNA™ or eRNA™) and proprietary programmable nanoparticles, aimed at revolutionizing medicine development with unprecedented performance and broad applicability.
Notable affiliated individuals include key scientists and executives from Flagship Pioneering, which is known for its track record in biotech innovation. Senda has achieved significant milestones in the field of programmable medicines, leveraging its rapid prototyping and testing bioplatform to build extensive data sets. This data enables the use of proprietary AI algorithms for the integrative design of RNA medicines. The company's impact lies in its potential to generate life-changing treatments, addressing a wide range of medical needs globally.
Companies similar to Senda Biosciences include Laronde, Senti Biosciences, Alltrna and Generate Biomedicines.
Senda Biosciences was founded in 2017.
Senda Biosciences' headquarters is located in Cambridge, MA, US.
Senda Biosciences' most recent funding round was for $123M (USD) in August 2022.
As of Aug 16, 2022, Senda Biosciences has raised a total of $309M (USD).
Senda Biosciences has 80 employees as of Feb 4, 2024.
Alltrna
alltrna.com
